News
VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitis
Regulatory News:
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the European Commission has approved Tavneos® in combination with a rituximab or cyclophosphamide regimen
CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220117005418/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with
Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211219005059/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215005992/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
CSL Limited announces tender offer to acquire Vifor Pharma Ltd
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global
GeNeuro erhält von der Schweizer Regierung Finanzmittel in Höhe von 6,7 Millionen Schweizer Franken (6,4 Millionen Euro) für die Entwicklung von Temelimab gegen Long COVID
GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), ein biopharmazeutisches Unternehmen, das neue Therapien für neurodegenerative und Autoimmunerkrankungen entwickelt, meldete heute, dass
Vifor Pharma comments on media speculation
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this
Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID
Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, with final
First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease
Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult
Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced the appointment of Hervé Gisserot as Chief Commercial Officer and member of the Vifor Pharma
Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
Vifor Pharma comments on market speculations
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Due to current market speculations, Vifor Pharma Group states the following:
Vifor Pharma Group systematically reviews options that
Vifor Pharma announces changes to the Executive Committee as CFO retires
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced that Colin Bond, Chief Financial Officer will retire from the company by the end of December 2021
Invitation: Straumann Group 2022 first-quarter sales webcast
Einladung: Straumann Group Webcast - Umsatzzahlen 1. Quartal 2022
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
DGAP-News: BB Biotech AG concludes its share buyback program and launches a new buyback program
DGAP-News: BB Biotech AG schliesst aktuelles Aktienrückkaufprogramm ab und lanciert ein neues Aktienrückkaufprogramm
Evolva's AGM postponed to May 5, 2022 / agenda remains unchanged
Straumann Group shareholders elect Nadia Tarolli Schmidt as a new Board member and approve all further proposals
Straumann Group Aktionärinnen und Aktionäre wählen Nadia Tarolli Schmidt als neues Mitglied des Verwaltungsrates und genehmigen alle weiteren Anträge
Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process
Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19